Mark G. Goldstein
Experienced in Plasmacytoma

Dr. Mark G. Goldstein

Hematology Oncology
Johns Hopkins Medicine
Center For Cancer & Blood Disorders
6410 Rockledge Drive, Suite 660, Suite 660, 
Bethesda, MD 
Offers Telehealth

Experienced in Plasmacytoma
Johns Hopkins Medicine
Center For Cancer & Blood Disorders
6410 Rockledge Drive, Suite 660, Suite 660, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Goldstein is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Goldstein is rated as an Experienced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Anal Cancer, Myelodysplastic Syndrome (MDS), and Pleuropulmonary Blastoma.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
University of Connecticut School of Medicine, Internal Medicine, 2005
Specialties
Hematology Oncology
Licenses
Internal Medicine in CT
Board Certifications
American Board Of Internal Medicine
Fellowships
University of Connecticut School of Medicine, Hematology and Oncology, 2008
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Center for Cancer & Blood Disorders
6410 Rockledge Drive, Suite 660, Suite 660, Bethesda, MD 20817
Call: 301-571-0019

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: October 20, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
View 6 Less Clinical Trials

3 Total Publications

IgG4-related Disease Presenting as a Pancreatic Mass and Bilateral Lacrimal Gland Swelling.
IgG4-related Disease Presenting as a Pancreatic Mass and Bilateral Lacrimal Gland Swelling.
Journal: Cureus
Published: April 04, 2017
View All 3 Publications
Similar Doctors
Distinguished in Plasmacytoma
Dr. Harvinder A. Singh
Hematology Oncology | Oncology | Hematology
Distinguished in Plasmacytoma
Dr. Harvinder A. Singh
Hematology Oncology | Oncology | Hematology

University Of Maryland Community Medical Group Inc

313 Hospital Dr, 
Glen Burnie, MD 
 (28.4 miles away)
410-761-1222
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Harvinder Singh is a Hematologist Oncology specialist and an Oncologist in Glen Burnie, Maryland. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Familial Colorectal Cancer, Pleuropulmonary Blastoma, Lung Cancer, Plasmacytoma, and Bone Marrow Aspiration. Dr. Singh is currently accepting new patients.

Advanced in Plasmacytoma
Dr. Aarthi G. Shenoy
Hematology Oncology | Hematology | Oncology
Advanced in Plasmacytoma
Dr. Aarthi G. Shenoy
Hematology Oncology | Hematology | Oncology

Medstar Medical Group Ii LLC

110 Irving St Nw, 
Washington, DC 
 (9.1 miles away)
202-877-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aarthi Shenoy is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Shenoy is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Follicular Lymphoma, and Bone Marrow Aspiration.

Advanced in Plasmacytoma
Dr. Ralph V. Boccia
Hematology Oncology | Oncology
Advanced in Plasmacytoma
Dr. Ralph V. Boccia
Hematology Oncology | Oncology

The Center For Cancer & Blood Disorders

6410 Rockledge Drive, Suite 660, Suite 660, 
Bethesda, MD 
 (2.1 miles away)
301-571-0019
Languages Spoken:
English, French, Spanish
See accepted insurances
Offers Telehealth

Dr. Ralph V. Boccia is a hematologist affiliated with Sibley Memorial Hospital, Suburban Hospital, Shady Grove Adventist Hospital, Holy Cross Hospital and MedStar Georgetown University Hospital, where he is a clinical associate professor of medicine for the University, as well as the medical director of the International Oncology Network (ION) Clinical Research Program and the chairman of ION’s Medical Advisory Panel. He practices out of the Center for Cancer and Blood Disorders, of which he is the founder and medical director, located in Bethesda, Maryland and Germantown, Maryland. Dr. Boccia earned his medical degree from the Autonomous University of Guadalajara School of Medicine. He completed a residency in internal medicine at Kern Medical Center, followed by a fellowship in hematology, oncology and bone marrow transplant at the combined UCLA-Veterans Administration Program and The National Cancer Institute at the National Institutes of Health. Dr. Boccia is a member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation. Dr. Boccia has been listed as a Top Doctor by Washingtonian Magazine and Consumers’ Checkbook Magazine since 1992. He has also been recognized as a Super Doctor by The Washington Post Magazine and a Regional Top Doctor for Washington, D.C., Baltimore and Washington-Baltimore by Castle Connolly. Dr. Boccia has contributed to various articles with his research, published in journals such as Annals of Internal Medicine, Journal of Clinical Oncology and The Lancet. Recent News Articles and Media Coverage Bladder cancer trends in Montgomery and Prince George's counties: Welcome news - and 3 facts you need to know. NJ.com (08/16/2016) RCCA Expands to Maryland to Become One of the Nation's First Multi-State Oncology/Hematology Physician-Owned and -Operated Networks. OncLive (10/06/2015). Dr. Boccia is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Anemia, Multiple Myeloma, Thrombocytopenia, Adult Immune Thrombocytopenia, and Splenectomy.

VIEW MORE PLASMACYTOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldstein's expertise for a condition
ConditionClose
    • Distinguished
    • Anal Cancer
      Dr. Goldstein is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Childhood Iron Deficiency Anemia
      Dr. Goldstein is
      Distinguished
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    • Myelodysplastic Syndrome (MDS)
      Dr. Goldstein is
      Distinguished
      . Learn about Myelodysplastic Syndrome (MDS).
      See more Myelodysplastic Syndrome (MDS) experts
    • Pleuropulmonary Blastoma
      Dr. Goldstein is
      Distinguished
      . Learn about Pleuropulmonary Blastoma.
      See more Pleuropulmonary Blastoma experts
    • Advanced
    • Astrocytoma
      Dr. Goldstein is
      Advanced
      . Learn about Astrocytoma.
      See more Astrocytoma experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Goldstein is
      Advanced
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    • Brain Tumor
      Dr. Goldstein is
      Advanced
      . Learn about Brain Tumor.
      See more Brain Tumor experts
    • Dehydration
      Dr. Goldstein is
      Advanced
      . Learn about Dehydration.
      See more Dehydration experts
    • Drug-Induced Thrombocytopenia
      Dr. Goldstein is
      Advanced
      . Learn about Drug-Induced Thrombocytopenia.
      See more Drug-Induced Thrombocytopenia experts
    • Embryonal Tumor with Multilayered Rosettes
      Dr. Goldstein is
      Advanced
      . Learn about Embryonal Tumor with Multilayered Rosettes.
      See more Embryonal Tumor with Multilayered Rosettes experts
    View All 26 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Goldstein is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Acquired Agranulocytosis
      Dr. Goldstein is
      Experienced
      . Learn about Acquired Agranulocytosis.
      See more Acquired Agranulocytosis experts
    • Acute Eosinophilic Pneumonia
      Dr. Goldstein is
      Experienced
      . Learn about Acute Eosinophilic Pneumonia.
      See more Acute Eosinophilic Pneumonia experts
    • Acute Mountain Sickness
      Dr. Goldstein is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Goldstein is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Goldstein is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    View All 127 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.